Targeted Agents, Immunotherapy Transforming Treatment Across NSCLC Spectrum
Mark G. Kris, MD, discusses the impact of targeted therapy in patients with EGFR-mutant NSCLC and the encouraging activity that has been reported with checkpoint inhibitors in advanced squamous disease.
Source: OncLive